Factors that affect reopening of blocked portal veins in people with cirrhosis and gastroesophageal varices
Official title: Indicators Affecting Portal Vein Thrombosis Recanalization in Cirrhosis With Gastroesophageal Varices
Run by Shanghai Zhongshan Hospital · NCT07473375 · Data updated 2026-11-12
This project looks at past records and follow-up to see which factors are linked with reopening (recanalization) of blocked portal veins in people who have cirrhosis and endoscopy-confirmed gastroesophageal varices.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 1500 (estimated) |
| Sponsor | Shanghai Zhongshan Hospital Academic / other |
| Locations | 1 site (Shanghai, Shanghai Municipality) |
| Status | Recruiting |
| Started | January 1, 2017 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2028 |
| Registry record updated | March 16, 2026 |
| Trial ID | NCT07473375 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal participants are people with cirrhosis and endoscopy-confirmed gastroesophageal varices who have portal vein thrombosis documented by CTA and complete anticoagulation treatment records, without liver cancer, extrahepatic malignancy, prior transplant or TIPS, or cavernous transformation.
✕Probably not a fit
Patients with hepatocellular carcinoma or other extrahepatic cancers, prior liver transplant or TIPS, cavernous transformation of the portal vein, or incomplete anticoagulation information are unlikely to benefit from this study's findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This retrospective-prospective study at Zhongshan Hospital, Fudan University examines patients with cirrhosis who have endoscopy-confirmed gastroesophageal varices and CT angiography–confirmed portal vein thrombosis (PVT). Researchers will review historical medical records and follow patients prospectively to collect imaging, anticoagulation treatment details, and clinical outcomes to identify factors associated with PVT recanalization. Key exclusions include hepatocellular carcinoma, extrahepatic malignancy, prior liver transplantation or TIPS, cavernous transformation of the portal vein, and missing anticoagulation data. The aim is to improve understanding of diagnosis, follow-up timing, and clinical management related to PVT recanalization.
Why it matters
Potential benefit: If successful, the findings could help clinicians predict who is likely to reopen blocked portal veins and tailor anticoagulation and follow-up to reduce complications.
How similar studies have gone: Other observational cohorts and anticoagulation studies have reported variable rates of PVT recanalization, so this work builds on existing but not definitive evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria:
* diagnosed as cirrhosis and confirmed gastroesophageal varices by endoscopy;
* all patients were diagnosed as PVT by CTA at admission.
Exclusion Criteria:
* patients with hepatocellular carcinoma;
* patients with extrahepatic malignancies;
* history of liver transplantation or TIPS;
* lack of information regarding anticoagulation therapy；
* those with cavernous transformation of the portal vein(CTPV) .
Where it's running
- Shanghai, Shanghai Municipality, China Recruiting
Study contacts
- Study coordinator: Siyu Jiang, Dr.
- Email: ksjsy1996926@126.com
- Phone: +86-15121068078
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Endovascular treatment outcomes after portal hypertension–related GI bleeding in cirrhosis
This study tests how well endovascular procedures for portal hypertension–related GI bleeding work in adults with cirrhosis, and what factors predict outcomes.
-
Apixaban plus carvedilol to prevent portal-hypertension complications in cirrhosis
This will test whether adding apixaban to carvedilol can help prevent variceal bleeding, portal vein thrombosis, and other portal-hypertension complications in adults with Child-Pugh B cirrhosis.
-
Apixaban for portal vein clots that appear more than a year after laparoscopic splenectomy
This trial tests whether taking apixaban twice daily can treat portal vein blood clots that develop more than a year after laparoscopic splenectomy in people with cirrhosis.
-
Apixaban for portal vein thrombosis occurring more than one year after laparoscopic splenectomy and azygoportal disconnection
This trial will try whether taking apixaban 2.5 mg twice daily can treat portal vein clots that appear more than a year after laparoscopic splenectomy and azygoportal disconnection in people with cirrhosis.
-
TIPS procedure with or without oral branched-chain amino acids (BCAA)
This test will try giving oral BCAA supplements for three months after TIPS in adults with cirrhosis and sarcopenia to see if it improves muscle and clinical outcomes.
-
Microplastics in the liver of people with cirrhosis and portal hypertension
This study tests whether microplastics and nanoparticles accumulate in the livers of adults with cirrhosis and portal hypertension who are undergoing surgery or transplant, to understand where they go and what form they take.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.